Market Overview

UPDATE: Bank of America Raises PO to $130 on Alexion Pharmaceuticals on Soliris Data

Share:
Related ALXN
Earnings Scheduled For October 26, 2017
Is A Beat In Store For Alexion This Earnings Season?
The Next Billion Dollar Blockbuster: Why Value Investors Should Look At Omeros Corporation (Part 1) (Seeking Alpha)

Bank of America reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) and raised its price objective from $118 to $130.

Bank of America commented, "We are increasing our PO from $118 to $130 to reflect a higher probability of success for Soliris in neuromyelitis optica (NMO) following impressive Phase 2 data presented yesterday. We removed MG and the nondescript "other indications" for Soliris from our valuation, as current data suggests NMO may be the final large indication beyond PNH and aHUS (STEC and AMR incremental drivers)."

Alexion Pharmaceuticals closed at $111.30 on Tuesday.

Latest Ratings for ALXN

DateFirmActionFromTo
Oct 2017Stifel NicolausMaintainsBuy
Oct 2017PiperJaffrayAssumesOverweightOverweight
Sep 2017RBC CapitalInitiates Coverage OnOutperform

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ALXN)

View Comments and Join the Discussion!

Partner Center